Details

Autor(en) / Beteiligte

• Yap, Desmond Y.H
• Seto, Wai Kay
• Fung, James
• Chok, Siu Ho
• Chan, See Ching
• Chan, Gary C.W
• Yuen, Man Fung
• Chan, Tak Mao

Titel

Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis

Ist Teil von

• Digestive and liver disease, 2017-02, Vol.49 (2), p.202-206

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Background Prediction of hepatorenal syndrome (HRS) remains difficult in advanced cirrhotic patients. Aims To evaluate use of serum and urine biomarkers to predict HRS. Methods We prospectively recruited Child’s B or C cirrhotic patients with normal serum creatinine, and followed them for 12 weeks for the development of HRS. Serum cystatin C (CysC), serum and urine Neutrophil Gelatinase-Associated Lipocalin (NGAL), serum and urine IL-18, serum N-acetyl-β-D glucosaminidase (NAG), urine kidney injury molecule-1 (KIM-1) and urine liver-type fatty acid binding protein (LFABP) were measured at recruitment (baseline), and their relationship with subsequent HRS investigated. Results 43 patients were included. 12 (27.9%) developed HRS at 7.3 ± 5.1 weeks from baseline. Logistic regression analysis showed that baseline urinary NGAL and urinary KIM-1 were significantly associated with the development of HRS (RR 1.007, 95% CI 1.001-1.012, p = 0.014; RR 1.973, 95% CI 1.002-3.886, p = 0.049). The cut-off values for NGAL and KIM-1 to predict HRS were 18.72 ng/mL and 1.499 ng/mL respectively (AUCs 0.84, p = 0.005; and 0.78, p = 0.008). Conclusion Urinary NGAL and KIM-1 could serve as biomarkers to predict HRS in advanced cirrhotic patients.